Company news
Neuren Pharmaceuticals Limited (ASX:NEU) news
Neuren Pharmaceuticals Limited news releases on 6ix. Latest, Sep 29, 2026: Trofinetide US patent protections extended to March 2041
Press releases & updates
Trofinetide US patent protections extended to March 2041
September 28, 2026
Growing royalty anchors Neuren first ever dividend program
August 25, 2026
European Commission grants marketing authorisation for DAYBU
August 24, 2026
Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
August 4, 2026
DAYBU recommended for approval in the European Union
June 28, 2026
Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
May 7, 2026
DAYBUE STIX now broadly available in US for Rett syndrome
April 8, 2026
Acadia confirms plan to request CHMP re-examination
March 2, 2026
2025 royalty income A$65m, profit after tax A$30m
February 26, 2026
Appendix 4E and 2025 full year accounts
February 26, 2026
Acadia reports DAYBUE net sales for 2025 and 2026 guidance
February 26, 2026
Pause in Trading
February 25, 2026
Neuren to commence new on-market share buy-back program
February 11, 2026
First patient dosed in Neuren PMS Phase 3 trial
February 5, 2026
Neuren receives US FDA meeting feeback for HIE and PTHS
February 4, 2026
Trading Halt
February 3, 2026
Acadia provides update on EU regulatory submission
February 2, 2026
Response to ASX Aware Letter
January 18, 2026
DAYBUE net sales projected to reach approx US$700m in 2028
January 13, 2026
FDA approves DAYBUE STIX (trofinetide), powder formulation
December 14, 2025
Record DAYBUE net sales of US$101.1 million in Q3 2025
November 5, 2025
Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid
October 19, 2025
Half Yearly Report and Accounts
August 26, 2025
First site initiated for Neuren's PMS Phase 3 trial
August 24, 2025
Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline
August 7, 2025
DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024
August 7, 2025
US patent allowed for NNZ-2591 to treat Pitt Hopkins
June 25, 2025
AGM Chair Address & CEO Presentation
May 27, 2025
DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
May 7, 2025
NEU confirms primary endpoints for Phase 3 trial in PMS
April 13, 2025
Neuren initiates development of NNZ-2591 to treat HIE
March 26, 2025
Neuren receives DAYBUE sales milestone payment of US$50m
February 28, 2025
2024 results - A$166m comprehensive income for shareholders
February 27, 2025
Appendix 4E and 2024 full year accounts
February 27, 2025
DAYBUE (trofinetide) 2024 net sales US$348 million
February 26, 2025
Neuren receives Rare Pediatric Disease Designation from FDA
February 23, 2025
Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
February 19, 2025
Priority Review Voucher sale proceeds received
February 7, 2025
Trofinetide marketing application submitted in Europe
January 14, 2025
Neuren announces A$50m on-market share buy-back program
November 13, 2024
Q3 2024 update
November 6, 2024
PRV sold for US$150m - Neuren to receive one third
November 5, 2024
DAYBUE receives marketing authorization in Canada
October 16, 2024
NEU continues PMS P3 preparations after positive FDA meeting
October 6, 2024
Phase 2 trial shows significant improvements in Angelman
August 9, 2024
Q2 2024 update
August 7, 2024
Phase 2 trial shows significant improvements in Pitt Hopkins
May 27, 2024
DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
May 9, 2024
Q1 2024 quarterly activity and cash flow report
April 24, 2024
Trofinetide accepted for Priority Review by Health Canada
April 23, 2024